Development of drug delivery systems that match the circadian rhythm

Pharmaceutical Journal

Volumn 274, Issue 7333, 2005, Pages 90-91

  Bryan, Jenny ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; EXCIPIENT; INSULIN; POLYMER; PROPRANOLOL; VERAPAMIL; WATER;

ARTHRITIS; ARTICLE; ASTHMA; BLOOD PRESSURE REGULATION; CANCER; CARDIOVASCULAR DISEASE; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; CLINICAL FEATURE; CONTROLLED RELEASE FORMULATION; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG RELEASE; DRUG RESEARCH; DUODENUM ULCER; EXPIRATION DATE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFUSION PUMP; INSULIN PUMP; MEMBRANE PERMEABILITY; NEUROLOGIC DISEASE; RISK ASSESSMENT;

EID: 13444301215     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Ross AC, MacRae RJ, Walther M, Stevens HN. Chronopharmaceutical drug deliveeery from a pulsatile capsule device based on programmable erosion. Journal of Pharmacy and Pharmacology 2000;52:903-9.
2. Youan B-BC. Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery. Journal of Controlled Release 2004;98:337-53.
3. Black HR, Elliot WJ, Grandits G, Grambsch P, Lucente T, White WB et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA 2003;289:2073-82.